N-Acetyl Cysteine In Schizophrenia Resistant to Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms [ 2016 - ]

Research Grant

Researchers: Prof David Castle (Principal investigator) ,  A/Pr Dan Siskind ,  A/Pr Paul Francis ,  Prof Anthony Harris ,  Prof Cherrie Galletly
View all 6 related researchers

Brief description Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.

Funding Amount $981,789.00

Funding Scheme Project Grants

Notes Standard Project Grant